



now it's personal

#### **INCEPTION PROGRAM**

Gil Sambrano, Ph.D.


Vice President Portfolio Development and Review





## **Funding Opportunities**





Program Offerings Per Year

## **CIRM 2.0 Inception Program**



## **Objective**

Provide **seed funding** for **great ideas** that may impact the field of human stem cell research but need modest support to test and compete for larger funding opportunities.

## **Emphasis of GWG Review**



- "Great new ideas" with potential to ultimately result in a translatable human stem/progenitor cell-based product or technology.
- Ideas with a sound scientific rationale is important, but preliminary data are <u>not</u> required or expected. This is a high risk, high reward program.
- We will provide \$150K to test the idea and generate data to compete for larger (more substantial) funding opportunities through CIRM or other sources.

## **Scoring System**



Tier 1: Score of "85-100"

Exceptional merit and warrants funding, if funds are available.

Tier 2: Score of "1-84"

Not recommended for funding.

Applications are scored by all scientific members of the GWG with no conflict.

### **DISC 1: GWG Recommendations**



	DISC1 Apps	Total Applicant Request
<b>Tier 1</b> : Score 85-100 Exceptional merit and warrants funding, if funds available	13	\$2,871,984
<b>Tier 2</b> : Score 1-84  Not recommended for funding	28	



# Overview of Recommended Applications



TITLE: iPSC-Derived Smooth Muscle Progenitors for Treatment of Abdominal Aortic Aneurysm

**UTILITY/DISEASE TARGET:** Aortic anuerysm

PRODUCT TYPE: Cell therapy



TITLE: Generation of human airway stem cells by direct transcriptional reprogramming for disease modeling and regeneration

UTILITY/DISEASE TARGET: Respiratory diseases

PRODUCT TYPE: In vitro disease model



TITLE: IVD rejuvenation using iPSC-derived notochordal cells

UTILITY/DISEASE TARGET: Intervertebral disc degeneration

PRODUCT TYPE: Cell therapy



TITLE: Enhanced Branching Morphogenesis and Pluripotent Cell Lineage Differentiation for Pediatric Regenerative Therapies

UTILITY/DISEASE TARGET: Kidney disease

PRODUCT TYPE: Combination cell/scaffold therapy



TITLE: Human Pancreatic Cancer Stem Cells: Developing a Novel Drug for Cancer Eradication

UTILITY/DISEASE TARGET: Pancreatic cancer

PRODUCT TYPE: Small molecule drug



TITLE: Optimizing self-renewal signaling kinetics to stabilize ex vivo hematopoietic stem cell expansion

UTILITY/DISEASE TARGET: Blood stem cell expansion

PRODUCT TYPE: Cell maintenance system



TITLE: Bone Marrow Targeting of Hematopoietic Stem Cells Engineered to Overexpress 25-OH-VD3 1-α-hydroxylase for Acute Myeloid Leukemia Therapy

UTILITY/DISEASE TARGET: Acute myeloid leukemia

PRODUCT TYPE: Gene-modified cell therapy



TITLE: Novel metabolic labeling method for tracking stem cells to irradiated salivary glands using PET

UTILITY/DISEASE TARGET: In vivo stem cell tracking

PRODUCT TYPE: Cell labeling methodology



TITLE: Identification of antigenic neo-epitopes from in vitro reprogrammed human tissue precursors for regenerative therapy

UTILITY/DISEASE TARGET: Immunogenicity of reprogrammed cells

PRODUCT TYPE: Tools to assess immune rejection



TITLE: Targeting cancer stem cells with nanoparticle RNAi delivery to prevent recurrence and metastasis of ovarian cancer

**UTILITY/DISEASE TARGET:** Ovarian cancer

PRODUCT TYPE: Nanoparticle RNAi



TITLE: An IPSC cell based model of macular degeneration for drug discovery

UTILITY/DISEASE TARGET: Age-related macular degeneration

PRODUCT TYPE: Cell-based drug screening tool



TITLE: Development of treatments to improve healing of ischemic wounds

UTILITY/DISEASE TARGET: Diabetic foot ulcers

PRODUCT TYPE: Combination cell/scaffold therapy



TITLE: Gingival mesenchymal stem cells as a novel treatment modality for periodontal tissue regeneration

**UTILITY/DISEASE TARGET: Periodontitis** 

PRODUCT TYPE: Combination cell/scaffold therapy